Clinical trials: Peripheral Revascularisation
Peripheral Artery Disease
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the…
- Trial name
- VOYAGER PAD (NCT02504216)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 532 sites in United States, Argentina and 32 more
- Volunteers
- 6,564 people
- Sponsor
- Bayer
Peripheral Arterial Disease
Intermittent Pneumatic Compression to Improve Revascularization Outcome
The purpose of this study is to investigate whether daily treatment with intermittent pneumatic leg compressions (IPC) following a nonsurgical vascular procedure improves circulation and enhances walking distance.
- Trial name
- NCT04250675
- Testing
- Intermittent pneumatic leg compressions
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Indiana University
Peripheral Artery Disease
Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization
To evaluate the safety and effectiveness of the Revolution™ Peripheral Atherectomy System in the treatment of infrainguinal lower extremity peripheral arterial occlusive disease.
- Trial name
- REVEAL (NCT02961894)
- Testing
- Revolution™ Peripheral Atherectomy System
- Where
- 17 sites in United States
- Volunteers
- 121 people
- Sponsor
- Rex Medical
Peripheral Arterial Disease, Intermittent Claudication
Exercise Rehabilitation in Veterans With PAD
Peripheral artery disease (PAD) results in blockages of arteries (blood vessels) and decreased blood flow to the legs. This may cause difficulty or pain with walking or other activities that use leg muscles.
- Trial name
- NCT02607046
- Testing
- Exercise training, NMES
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Critical Limb Ischemia
Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia
A Prospective, Randomized, Single-center Pilot Study of The OxyGenesys(TM) Dissolved Oxygen Dressing to Improve Chronic Wound Healing after REvascularization for Critical Limb Ischemia.
- Trial name
- NCT02046226
- Testing
- Oxygenesys(TM) Dissolved Oxygen Dressing
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Halyard Health
Peripheral Artery Disease (PAD)
Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR
To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have…
- Trial name
- TI-PAD EVR (NCT02227368)
- Testing
- Ticagrelor, Comparator
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Peripheral Vascular Disease
Tele-Health Electronic Monitoring to Reduce Post Discharge Complications and Surgical Site Infections
Abstract: It is intuitive that post discharge surgical complications are associated with increased patient dissatisfaction, and directly associated with an increase in medical expenditures.
- Trial name
- THEM (NCT02767011)
- Testing
- Tele-Health Electronic Monitoring (THEM)
- Volunteers
- 30 people
- Sponsor
- CAMC Health System
Peripheral Artery Disease
Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH)
The purpose of this study is to evaluate the safety of two doses of PVS-10200, an allogeneic cellular therapy, delivered as a single injection following percutaneous transluminal ("balloon") angioplasty and stent placement for…
- Trial name
- TRIUMPH (NCT01099215)
- Testing
- PVS-10200
- Where
- 3 sites in France
- Volunteers
- 21 people
- Sponsor
- Shire
Peripheral Arterial Disease
A Study of Loco-Regional Liposomal Bupivacaine Injection
The purpose of this research is to find out if using liposomal bupivacaine solution (bupivacaine liposome) injections during lower extremity revascularization surgery will lower the amount of narcotic drugs used during and…
- Trial name
- NCT05992896
- Testing
- Bupivacaine liposome
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Peripheral Arterial Disease
TORUS I Clinical Study
The primary objective of the feasibility study is to evaluate the safety and effectiveness of the PQ Bypass Stent Graft System in the treatment of atherosclerotic lesions of the native superficial femoral artery (SFA) or the…
- Trial name
- NCT03128424
- Testing
- PQ Bypass Stent Graft System
- Volunteers
- 60 people
- Sponsor
- Endologix
Peripheral Arterial Disease
Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
The purpose of this study is to evaluate whether clopidogrel 75 mg daily on a background of aspirin 75-100 mg/d for clinically indicated duration or for an additional 12 months will lead to an increased rate of primary patency…
- Trial name
- ASPIRE (NCT02217501)
- Testing
- Clopidogrel, Acetylsalicylic acid (ASA)
- Where
- 4 sites in United States
- Volunteers
- 159 people
- Sponsor
- University of Texas Southwestern Medical Center
Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease
Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease
The PATHFINDER Registry is a prospective, non-randomized, single arm, multicenter observational study. This pilot registry is aimed to evaluate the performance (peri-procedural) and clinical outcomes (intermediate and long-term)…
- Conditions
- Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease, PAD
- Trial name
- PATHFINDER (NCT04229563)
- Testing
- AURYON Atherectomy System
- Where
- 10 sites in United States
- Volunteers
- 102 people
- Sponsor
- Angiodynamics, Inc.
Peripheral Arterial Disease
The PQ Bypass Pivotal IDE Intra-arterial Stent Graft Study
The primary objective of the TORUS 2 IDE Clinical Study is to evaluate the safety and effectiveness of the TORUS Stent Graft System in the treatment of obstructive atherosclerotic lesions of the native SFA or the superficial…
- Trial name
- TORUS2 (NCT04130737)
- Testing
- TORUS Stent Graft System
- Where
- 32 sites in United States
- Volunteers
- 188 people
- Sponsor
- Endologix
Myocardial Infarction, Stroke
Women's Health Initiative Strong and Healthy Study
The WHISH trial applies state-of-the science behavioral principles and currently available technologies to deliver a physical activity intervention without face-to-face contact to ~25,000 older U.S. women expected to consent.
- Conditions
- Myocardial Infarction, Stroke, Cardiovascular Mortality, Hip Fractures
- Trial name
- WHISH (NCT02425345)
- Testing
- Physical Activity
- Volunteers
- 49,331 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Peripheral Vascular Disease
Effects of Paclitaxel on Intimal Hyperplasia
This is a single, one time, limited dose infusion of Paclitaxel, that will potentially prevent recurrent stenosis secondary to intimal hyperplasia when compared to the control group at 10 months.
- Trial name
- Pac1 (NCT01454778)
- Testing
- Paclitaxel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Patrick Kelly
Peripheral Arterial Disease
The DETOUR 2 Clinical Trial
Prospective, single-arm, multi-center, international clinical investigation to evaluate the safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant stent grafts for a percutaneous…
- Trial name
- NCT03119233
- Testing
- DETOUR System
- Where
- 34 sites in United States, Germany and 1 more
- Volunteers
- 202 people
- Sponsor
- Endologix
Peripheral Arterial Disease, Claudication (Finding)
Cilostazol After Lower Extremity Arterial Revascularization Trial
Twenty patients will be recruited to CLEAR. Ten will be randomized to the treatment arm (Cilostazol) and tenwill be randomized to the control group. Patients randomized to the treatment arm will receive Cilostazol for 90 days.
- Trial name
- CLEAR (NCT02374957)
- Testing
- Cilostazol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Vascular Disease, Peripheral
Prevention of Restenosis Following Revascularization
The purpose of this study is to investigate the prevention of Restenosis following Revascularization of the superficial Femoral Artery (SFA)
- Trial name
- NCT00518284
- Testing
- Nanoparticle Paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 6 people
- Sponsor
- Celgene Corporation